Adalina Sacco1, Lynn Simpson2, Jan Deprest1,3, Anna L David1,3,4. 1. Institute for Women's Health, University College London, London, UK. 2. Maternal Fetal Medicine division, Columbia University Medical Center, Manhattan, NY, USA. 3. Department of Development and Regeneration, Cluster Woman and Child, Biomedical Sciences, Leuven, Belgium. 4. NIHR University College London Hospitals Biomedical Research Centre, London, UK.
Abstract
AIM: To establish the provision of fetal surgery for myelomeningocele (MMC) worldwide. METHODS: Through the International Society for Prenatal Diagnosis (ISPD) Fetal Therapy Special Interest Group and the North American Fetal Therapy Network (NAFTNet), fetal therapy centres were surveyed (September 2017-June 2018) regarding availability of fetal MMC surgical repair, patient inclusion criteria, repair techniques, number of cases, and outcome reporting. Responses were summarised on an interactive map on the ISPD website. RESULTS: Forty-four of 59 centres responded (74.6%) of which 34 centres (77.1%) currently offered fetal surgery for MMC and seven centres (15.9%) were awaiting a first case after service set up. Patient inclusion criteria were similar and based on the Management of Myelomeningocele (MOMS) trial. Five centres (14.7%) operated beyond 26 weeks' gestational age, outside the MOMS criteria. Open fetal surgery was provided in 23 centres (67.6%), fetoscopic surgery only in five (14.7%), and six centres offered both types (17.6%). Neurosurgical closure was similar for open surgery but highly variable in fetoscopy surgery. The median number of cases per centre was 21 (range 1-253). CONCLUSIONS: Fetal surgery for MMC is now offered globally. Two thirds of centres offer open repair via hysterotomy using criteria based on the MOMS trial.
AIM: To establish the provision of fetal surgery for myelomeningocele (MMC) worldwide. METHODS: Through the International Society for Prenatal Diagnosis (ISPD) Fetal Therapy Special Interest Group and the North American Fetal Therapy Network (NAFTNet), fetal therapy centres were surveyed (September 2017-June 2018) regarding availability of fetal MMC surgical repair, patient inclusion criteria, repair techniques, number of cases, and outcome reporting. Responses were summarised on an interactive map on the ISPD website. RESULTS: Forty-four of 59 centres responded (74.6%) of which 34 centres (77.1%) currently offered fetal surgery for MMC and seven centres (15.9%) were awaiting a first case after service set up. Patient inclusion criteria were similar and based on the Management of Myelomeningocele (MOMS) trial. Five centres (14.7%) operated beyond 26 weeks' gestational age, outside the MOMS criteria. Open fetal surgery was provided in 23 centres (67.6%), fetoscopic surgery only in five (14.7%), and six centres offered both types (17.6%). Neurosurgical closure was similar for open surgery but highly variable in fetoscopy surgery. The median number of cases per centre was 21 (range 1-253). CONCLUSIONS: Fetal surgery for MMC is now offered globally. Two thirds of centres offer open repair via hysterotomy using criteria based on the MOMS trial.
Authors: Sandra K Kabagambe; Guy W Jensen; Yue Julia Chen; Melissa A Vanover; Diana L Farmer Journal: Fetal Diagn Ther Date: 2017-09-15 Impact factor: 2.587
Authors: Michael V Zaretsky; Kenneth W Liechty; Henry L Galan; Nicholas J Behrendt; Shane Reeves; Ahmed I Marwan; Corbett Wilkinson; Michael Handler; Megan Lagueux; Timothy M Crombleholme Journal: Fetal Diagn Ther Date: 2017-09-06 Impact factor: 2.587
Authors: Samer K Elbabaa; Anne M Gildehaus; Matthew J Pierson; J Andrew Albers; Emanuel J Vlastos Journal: Childs Nerv Syst Date: 2017-05-03 Impact factor: 1.475
Authors: Julie S Moldenhauer; Shelly Soni; Natalie E Rintoul; Susan S Spinner; Nahla Khalek; Juan Martinez-Poyer; Alan W Flake; Holly L Hedrick; William H Peranteau; Norma Rendon; Jamie Koh; Lori J Howell; Gregory G Heuer; Leslie N Sutton; Mark P Johnson; N Scott Adzick Journal: Fetal Diagn Ther Date: 2014-08-15 Impact factor: 2.587
Authors: Céline Ovaere; Alex Eggink; Jute Richter; Titia E Cohen-Overbeek; Frank Van Calenbergh; Katrien Jansen; Dick Oepkes; Roland Devlieger; Luc De Catte; Jan A Deprest Journal: Fetal Diagn Ther Date: 2014-10-03 Impact factor: 2.587
Authors: Yada Kunpalin; Sindhu Subramaniam; Silvia Perin; Mattia F M Gerli; Jan Bosteels; Sebastien Ourselin; Jan Deprest; Paolo De Coppi; Anna L David Journal: Prenat Diagn Date: 2021-01-11 Impact factor: 3.242
Authors: Adalina Sacco; Fred Ushakov; Dominic Thompson; Donald Peebles; Pranav Pandya; Paolo De Coppi; Ruwan Wimalasundera; George Attilakos; Anna Louise David; Jan Deprest Journal: Obstet Gynaecol Date: 2019-09-27
Authors: Neeltje Crombag; Adalina Sacco; Bernadette Stocks; Philippe De Vloo; Johannes van der Merwe; Katie Gallagher; Anna David; Neil Marlow; Jan Deprest Journal: Prenat Diagn Date: 2021-07-18 Impact factor: 3.242